# IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors

> **NCT05972460** · PHASE1 · UNKNOWN · sponsor: **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** · enrollment: 108 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** IMM2510

## Key facts

- **NCT ID:** NCT05972460
- **Lead sponsor:** ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-18
- **Primary completion:** 2023-12
- **Final completion:** 2024-10
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2023-08-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05972460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05972460, "IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05972460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*